Moyneur E, et al. - Researchers analyzed data of women with vulvovaginal atrophy from the Truven Health MarketScan Commercial and Medicare Supplemental Databases (January 2010-September 2016) who had ≥ 365 days of continuous insurance coverage before and after the first vulvovaginal atrophy/dyspareunia diagnosis (index date) in order to determine how vulvovaginal atrophy is correlated with depression, major depressive disorder, and anxiety. They matched women with vulvovaginal atrophy 1:3 to women without (controls) with respect to age, calendar year, health plan, and region. Inclusion of overall 125,889 women with vulvovaginal atrophy and 376,057 controls was done (mean age 60.7 [45-101]). The analysis revealed a significantly higher prevalence/incidence of depression, major depressive disorder, and anxiety in correlation with vulvovaginal atrophy. Younger women exhibited a higher prevalence/incidence and greater differences highlighting the necessity for a multidisciplinary approach and early diagnosis/management of vulvovaginal atrophy.